Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/13/2008

ketable securities 4,410 -

Accounts receivable, net 5,310 5,389

Inventories 2,200 2,213

Prepaid expenses 3,210 3,224

Other current assets 1,346 381

Total current assets 119,245 116,091

Property and equipment, net 3,875 3,941

Intangible assets, net 74,919 36,040

Goodwill 38,213 38,213

Long-term restricted cash and

investments - 12,000

Other long-term assets 2,766 1,269

Total assets $239,018 $207,554

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Line of credit $3,180 $3,459

Accounts payable 8,915 2,856

Accrued liabilities 30,133 29,047

Purchased product rights liability 31,000 -

Deferred revenue 1,494 1,494

Total current liabilities 74,722 36,856

Non-current portion of deferred revenue 12,183 12,468

Liability under government settlement 13,063 14,881

Senior secured notes 113,367 75,116

Common stock subject to repurchase 13,241 13,241

Stockholders' equity 12,442 54,992

Total liabilities and stockholders'

equity
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medimetriks Pharmaceuticals, Inc. Begins Operations
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
5. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
6. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
7. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
8. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
9. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
10. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
11. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  AnaptysBio, Inc., a leader in the ... announced the advancement of its first-in-class anti-interleukin-36 ... The Company,s anti-IL-36R therapeutic antibody, called ANB019, ... psoriasis (GPP), an orphan systemic inflammatory disease ... owned within AnaptysBio,s proprietary antibody pipeline and ...
(Date:4/16/2015)... 16, 2015  EMD Serono today announced the ... Germany , appointed Alise Reicin ... Global Clinical Development.  Dr. Reicin brings extensive research ... Oncology and Immunology. She is an accomplished pharmaceutical ... a Vice President in various capacities across R&D ...
(Date:4/16/2015)... 16, 2015 Fairleigh Dickinson University ... Gulfo to become the Executive Director of the ... announced the kick-off of the Initiative for Patient ... Dr. Gulfo, under the Rothman Institute of Innovation ... and in collaboration with FDU’s School of Pharmacy’s ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a ... small molecule therapeutics for,the treatment of cancer, today ... JMP Securities Healthcare Focus Conference in Boston. ... p.m. (Eastern) on,Tuesday, November 13, 2007. There will ...
... ... treatment issues, SAN RAMON, Calif., Nov. 7 ... advisory group,designed to tackle head-on the increasingly complex ethical issues of,infertility medicine ... RSC,s ethics committee, believed to be the second of its kind among,infertility ...
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials ... tissue repair and drug delivery,products, announced today that ... the Securities and Exchange Commission (SEC) that, if,declared ... sell, from time to,time, up to $20 million ...
Cached Biology Technology:Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference 2California IVF Experts Tap Ethics Committee for Guidance 2SyntheMed Files Universal Shelf Registration 2
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... CORVALLIS, Ore. A new study by Oregon State ... often know what kinds of foods they should be eating, ... money for meals. Joan Gross and Nancy Rosenberger, both ... rural Oregonians living in poverty by conducting in-depth interviews with ...
... it is for pregnant women to eat good, nutritious food. ... children who are less likely to develop type 1 diabetes, ... at the University of Gothenburg, Sweden. The ... conducting a population study called ABIS (All Babies in Southeast ...
... Ala. An experimental drug cocktail that includes ... hope in developing a single agent to treat ... in the University of Alabama Birmingham (UAB) Division ... the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) ...
Cached Biology News:Poor in rural Oregon face 'double binds' when getting food 2Poor in rural Oregon face 'double binds' when getting food 3Vegetables can protect unborn child against diabetes 2Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... Recombinant DNA polymerase from Thermus aquaticus expressed ... contamination; 1 tube of 250 units enzyme/tube ... (Low DNA), is the same enzyme as ... through a proprietary separation process to ensure ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
Taq DNA polymerase, 10,000U...
Biology Products: